- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07670923
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Inclusion Criteria
- Patients scheduled for elective non-intubated general anesthesia
- Age ranging from 65 to 80 years old
- American Society of Anesthesiologists (ASA) physical status class I-III
- Written informed consent signed by the patient or legal guardian
Exclusion Criteria
- Confirmed allergy to propofol, ciprofol or their excipients
- Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
- Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
- Severe hepatic or renal insufficiency
- Long-term regular use of sedatives or opioids
- Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%) Elimination Criteria
1. Patients with allergic reactions to study drugs or other severe complications during the trial
2. Severe hypoxemia requiring emergency endotracheal intubation
3. Severe hemodynamic instability occurring during induction
4. Incomplete monitoring data caused by equipment malfunction Randomization and Group Allocation A total of 108 eligible elderly patients undergoing elective non-intubated general anesthesia at the Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University will be recruited. A computer-generated random number sequence will allocate subjects at a 1:1 ratio into the ciprofol group (Group C) and the propofol group (Group P).
Observation Indicators
Baseline Demographic Data
Gender, age, height, weight, BMI, ASA classification, smoking history, alcohol consumption, underlying diseases, Modified Mallampati score, thyromental distance, snoring history, etc.
Primary Observation Indicators
Hemodynamic parameters (Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR)) and respiratory parameters (peripheral oxygen saturation (SpO₂), respiratory rate (RR), end-tidal carbon dioxide (EtCO₂)) will be recorded at baseline, loss of consciousness, 30 s, 1 min, 2 min, 3 min, 4 min and 5 min after loss of consciousness.
Secondary Observation Indicators
- Baseline BIS value and minimum BIS value during induction
- Total induction dosage, induction time (from drug administration to MOAA/S ≤ 1), recovery time (from last drug administration to MOAA/S = 5)
- Incidence of adverse reactions: injection pain, involuntary movement, hiccup, hypotension, bradycardia, hypoventilation, apnea, hypoxemia, etc.
Anesthetic Protocol
All patients fast for 8 hours and abstain from clear liquids for 4 hours preoperatively. After entering the operating room, oxygen inhalation is initiated, upper limb venous access is established, and monitors including pulse oximetry, sidestream PETCO₂ monitor, continuous non-invasive arterial blood pressure monitor and bispectral index (BIS) monitor are connected.
Midazolam 0.01 mg/kg is administered intravenously first; stable circulatory and respiratory readings thereafter serve as baseline values. Ciprofol or propofol is then infused intravenously at 10 mL/min. Sedation depth is assessed every 5 seconds via MOAA/S scale; drug infusion is stopped once MOAA/S ≤ 1 (loss of consciousness). The total induction dose is recorded. All hemodynamic and respiratory indicators are documented at predefined time points.
Anesthesiologists may supplement 1/3 of the initial induction dose if the patient shows eye opening, verbal response or body movement, with an interval of at least 1 minute between supplemental doses.
Rescue Management Protocols
- Hypotension (SBP < 90 mmHg or MAP decreased by >20% from baseline lasting >2 min): ephedrine 6 mg IV
- Severe bradycardia (HR < 45 beats/min lasting >30 s): atropine 0.5 mg IV
- Hypoventilation (RR < 8 bpm, PETCO₂ less than half baseline or PETCO₂ ≥45 mmHg lasting >30 s)
- Apnea (no thoracic movement or flat PETCO₂ waveform lasting >10 s)
- Hypoxemia (SpO₂ < 93%) / severe hypoxemia (SpO₂ < 85%) For respiratory compromise, jaw thrust, increased oxygen flow or mask-assisted ventilation will be applied; emergency endotracheal intubation will be performed if necessary.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 4
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Hanxiang Ma Ma, master
- Puhelinnumero: 13519591508
- Sähköposti: mahanxiang@hotmail.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: LI Mo Mo, Bachelor
- Puhelinnumero: 17752025907
- Sähköposti: ml185030153@163.com
Opiskelupaikat
-
-
Ningxia
-
Yinchuan, Ningxia, Kiina, 750000
- Rekrytointi
- Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Patients scheduled for elective non-intubated general anesthesia
- Age ranging from 65 to 80 years old
- American Society of Anesthesiologists (ASA) physical status class I-III
- Written informed consent signed by the patient or legal guardian
Exclusion Criteria:
- Confirmed allergy to propofol, ciprofol or their excipients
- Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
- Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
- Severe hepatic or renal insufficiency
- Long-term regular use of sedatives or opioids
- Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Ciprofol treatment group
This group plans to enroll a total of 54 elderly patients aged 65-80 who will undergo brief procedures without intubation, using spontaneous respiration under general anesthesia.
The intravenous infusion of cyclopropane hydrochloride injection will be administered at a constant rate of 10 ml/min.
The administration will cease when the MOAA/S score is ≤1.
Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR), and respiratory parameters (SpO₂, respiratory rate (RR), PETCO₂), and various anesthetic adverse reactions will be monitored within the first 5 minutes after induction.
The safety of the medication will be evaluated in comparison with the control group
|
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point.
This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
|
|
Active Comparator: Propofol Control group
This study aims to enroll 54 elderly patients aged 65-80 with short procedures and no need for intubation, who will receive propofol intravenously at a constant rate of 10 ml/min until their MOAA/S score drops to ≤1 point.
Circulatory and respiratory parameters, as well as adverse events, will be recorded simultaneously 5 minutes after induction.
This will allow for a parallel comparison of the two medications' effects on the circulatory and respiratory systems of elderly patients with the propofol control group.
|
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point.
This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Comparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction
Aikaikkuna: 5 minutes after induction of anesthesia
|
The primary objective of this study was to evaluate the degree of circulatory and respiratory suppression induced by two types of anesthesia drugs in elderly patients.
Continuous, non-invasive monitoring was conducted on the baseline conditions before administration for patients aged 65 to 80 undergoing short procedures without intubation and with spontaneous respiration under general anesthesia.
Additionally, measurements were taken at 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes after induction to assess circulatory and respiratory functions.
Statistical analysis was performed to compare the changes in Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, cardiac output , stroke volume, systemic vascular resistance , peripheral oxygen saturation, respiratory rate , end-tidal carbon dioxid within the 5-minute induction period.
A comprehensive assessment of the dual safety of circulatory and respiratory systems was conducted
|
5 minutes after induction of anesthesia
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Brain electrical activity sedation depth (BIS)
Aikaikkuna: 5 minutes after induction of anesthesia
|
lowest BIS value throughout the induction process, BIS value immediately upon loss of consciousness.
|
5 minutes after induction of anesthesia
|
|
incidence of induction period circulatory/respiratory adverse events
Aikaikkuna: 5 minutes after induction of anesthesia
|
Proportion of adverse events, including low blood pressure, bradycardia, inadequate ventilation, apnea, and hypoxemia, occurring within 5 minutes of induction
|
5 minutes after induction of anesthesia
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- Li Mo-2026-06-22
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .